David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn:
”This year 2 PHRC K were obtain by FFCD:
- EPITFOX (Marie Muller): TFOX +/- IO (vs FOLFOX) in suqamous cell carcinoma of oesophagus.
- NIMOGREL (Anthony Turpin): FOLFIRI plus Nimotuzumab (vs FOLFIRI) in small bowel adenocarcinoma.
About 15 new FFCD/PRODIGE trials in digestive oncology will start in 2025-2027!”